Bluebird bio completes split into two companies; BeiGene builds out Brukinsa data at ASH
Bluebird bio has been officially split in half.
Both sides of the once-singular cell and gene therapy company announced Thursday they have completed their split into two biotechs: A gene therapy-focused outfit that will retain the old avian name and a new oncology-focused firm that will go by 2seventy bio.
The move, executives say, will allow each company to focus on bringing therapies to market in fields that require very different types of expertise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.